Stéphane Renaud1,2, Joseph Seitlinger3, Yaseen Al Lawati2, Francesco Guerrera4, Pierre-Emmanuel Falcoz3, Gilbert Massard3, Lorenzo Ferri2, Jonathan Spicer2. 1. Department of Thoracic Surgery, Nancy University Hospital, Nancy, France. 2. Department of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Center, Montreal. Canada. 3. Department of Thoracic Surgery, Strasbourg University Hospital, Strasbourg, France. 4. Department of Thoracic Surgery, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
Abstract
OBJECTIVE: The aim of this study was to evaluate the benefit of anatomical resection (AR) in lung metastasectomy (LM) of colorectal cancer (CRC) harboring KRAS mutations SUMMARY BACKGROUND DATA:: KRAS mutations are related to high aggressiveness in the lung metastasis of CRC. It is unknown whether AR can lead to better outcomes than can non-AR (NAR) in KRAS patients. METHODS: We retrospectively reviewed the data from 574 consecutive patients who underwent a LM for CRC. We focused on patients exhibiting 1 lung metastasis who underwent an AR (segmentectomy) or an NAR (wedge) and for whom the KRAS mutational status was known. Overall survival (OS) and time to pulmonary recurrence (TTPR) were analyzed. RESULTS: We included 168 patients, of whom 95 (56.5%) harbored KRAS mutations. An AR was performed in 74 patients (44%). The type of resection did not impact the median OS in wild-type (WT) patients (P = 0.67) but was significantly better following AR in KRAS patients (101 vs 45 months, P = 0.02) according to the multivariate analysis [hazard ratio (HR): 6.524; 95% confidence interval (CI), 2.312-18.405; P < 0.0001). TTPR was not affected by the type of resection in WT patients (P = 0.32) but was significantly better for AR in KRAS patients (50 vs 15 months, P = 0.01) in the multivariate analysis (HR: 5.273; 95% CI, 1.731-16.064; P = 0.003). The resection-margin recurrence rate was significantly higher for NAR in KRAS patients (4.8% vs 54.2%, P = 0.001) but not in WT patients (P = 0.97). CONCLUSION: AR seems to improve both the OS and TTPR in LM of CRC harboring KRAS mutations.
OBJECTIVE: The aim of this study was to evaluate the benefit of anatomical resection (AR) in lung metastasectomy (LM) of colorectal cancer (CRC) harboring KRAS mutations SUMMARY BACKGROUND DATA:: KRAS mutations are related to high aggressiveness in the lung metastasis of CRC. It is unknown whether AR can lead to better outcomes than can non-AR (NAR) in KRASpatients. METHODS: We retrospectively reviewed the data from 574 consecutive patients who underwent a LM for CRC. We focused on patients exhibiting 1 lung metastasis who underwent an AR (segmentectomy) or an NAR (wedge) and for whom the KRAS mutational status was known. Overall survival (OS) and time to pulmonary recurrence (TTPR) were analyzed. RESULTS: We included 168 patients, of whom 95 (56.5%) harbored KRAS mutations. An AR was performed in 74 patients (44%). The type of resection did not impact the median OS in wild-type (WT) patients (P = 0.67) but was significantly better following AR in KRASpatients (101 vs 45 months, P = 0.02) according to the multivariate analysis [hazard ratio (HR): 6.524; 95% confidence interval (CI), 2.312-18.405; P < 0.0001). TTPR was not affected by the type of resection in WTpatients (P = 0.32) but was significantly better for AR in KRASpatients (50 vs 15 months, P = 0.01) in the multivariate analysis (HR: 5.273; 95% CI, 1.731-16.064; P = 0.003). The resection-margin recurrence rate was significantly higher for NAR in KRASpatients (4.8% vs 54.2%, P = 0.001) but not in WTpatients (P = 0.97). CONCLUSION:AR seems to improve both the OS and TTPR in LM of CRC harboring KRAS mutations.
Authors: Federico Davini; Sara Ricciardi; Carmelina C Zirafa; Gaetano Romano; Greta Alì; Gabriella Fontanini; Franca M A Melfi Journal: Int J Colorectal Dis Date: 2019-11-04 Impact factor: 2.571
Authors: Georgios Antonios Margonis; Martin E Kreis; Jaeyun Jane Wang; Carsten Kamphues; Christopher L Wolfgang; Matthew J Weiss Journal: Hepatobiliary Surg Nutr Date: 2020-12 Impact factor: 7.293
Authors: Elena Prisciandaro; Laurens J Ceulemans; Dirk E Van Raemdonck; Herbert Decaluwé; Paul De Leyn; Luca Bertolaccini Journal: J Thorac Dis Date: 2022-07 Impact factor: 3.005